China's JD Health interim revenue rises on user growth, product expansion

JD Health International

13/08/2026 09:42

Overview
China healthcare platform's interim revenue rose 15.9% yr/yr to RMB40.9 bln
Net income attributable to shareholders increased to RMB3.4 bln from RMB2.6 bln
Growth driven by expanded product offering and increased active user accounts

Outlook
JD Health did not provide specific financial guidance for the current quarter or full year in the press release 

Result Drivers
PRODUCT REVENUE GROWTH - Co said revenue growth was mainly driven by more active user accounts, higher purchase frequency, and a broader product range
SERVICE REVENUE - Service revenue rose due to more advertisers and higher transaction volumes on the platform
SUPPLY CHAIN & AI INTEGRATION - Improved gross profit margin attributed to enhanced supply chain capabilities and deeper integration of AI technologies

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 40.89 bln
 
H1 Net Income Attributable
 
RMB 3.44 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for JD Health International Inc is HK$67.45, about 73.6% above its August 12 closing price of HK$38.86
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 12 - Hong Kong's Qianhai Health interim revenue falls on supply constraints
Aug 10 - Telehealth platform Hims & Hers swings to Q2 net loss as margin pressure offsets revenue growth
Aug 11 - Legend Biotech Q2 revenue beats estimates on commercial expansion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-13/9b76c52a-36f3-45de-82e2-21ba475cc4a5.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)